OpGen Inc (NASDAQ:OPGN) traded up 3.7% on Thursday . The stock traded as high as $0.29 and last traded at $0.28, 3,761 shares changed hands during mid-day trading. A decline of 97% from the average session volume of 145,143 shares. The stock had previously closed at $0.27.
Several equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $1.50 price objective on shares of OpGen in a report on Sunday, May 19th. Zacks Investment Research cut OpGen from a “buy” rating to a “hold” rating in a report on Tuesday, June 18th. Finally, ValuEngine raised OpGen from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
The stock has a market capitalization of $4.75 million, a price-to-earnings ratio of -0.13 and a beta of 0.83. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.78 and a current ratio of 0.89. The company has a fifty day simple moving average of $0.32 and a two-hundred day simple moving average of $0.66.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp acquired a new position in OpGen in the 4th quarter valued at $27,000. Susquehanna International Group LLP acquired a new position in shares of OpGen during the 2nd quarter worth $28,000. Finally, Virtu Financial LLC acquired a new position in shares of OpGen during the 1st quarter worth $70,000. 10.31% of the stock is owned by hedge funds and other institutional investors.
About OpGen (NASDAQ:OPGN)
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
Featured Article: Discount Rate
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.